AUCTORES
Globalize your Research
Review Article
*Corresponding Author: Afroj A. Shaikh, Department of Pharmacy, HSBPVT’S, GOI, College of Pharmacy, Kashti, Shrigonda 413701, Maharashtra, India.
Citation: Afroj A. Shaikh and Sachin J. Anbhule, (2023), Cephalosporins: A Comprehensive Review and Anticipated Directions for the Future, J. Pharmaceutics and Pharmacology Research, 6(6); DOI: 10.31579/2693-7247/137
Copyright: © 2023, Afroj A. Shaikh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 07 July 2023 | Accepted: 10 August 2023 | Published: 08 December 2023
Keywords: cephalosporins; future prospects; spectrum of activity; antimicrobial spectrum; five generations; bacterial resistance; current scenario
Bacterial infections are very commonly acquired infections. Cephalosporins are broad-spectrum antibiotics used to manage a wide-variety of infections caused by gram-positive and gram-negative bacteria. The knowledge of the basic chemistry helps in understanding the pharmacokinetic, antimicrobial and toxicological profiles of cephalosporins. Cephalosporins are antibiotics with bactericidal activity which act by inhibiting the synthesis of cell wall in bacteria. The drugs of this class are classified into five generations in which the antimicrobial spectrum shifts from gram-positive bacteria to gram-negative bacteria with increasing generations of Cephalosporins. Antibiotic-producing bacteria contain a wide range of complex defense mechanisms to protect themselves from their own antibiotics and it results in the development of antibiotic resistance. The various mechanisms by which bacteria develop resistance are: production of β-lactamases, alteration of the porin channels, alteration of molecular structure of transpeptidase, and upregulation of cephalosporin efflux pumps. The new cephalosporins are the foundation for the real warning signs to open up new and interesting possibilities for serious infections in the future thereby ensuring rational selection of antibiotics for various infections.
Infection due to various types of micro-organisms is always a part of our life (human life). Bacterial infections are very normally acquired infections. Different types of bacteria are beneficial to human beings and also to other living things which live in soil, in water and on plants as well as some of bacteria are responsible for generating an infection in human body or living things like typhoid, cholera, plague, pneumonia, and tuberculosis.1 In developing nations like India, where Gram-positive and Gram-negative bacteria are prevalent and linked to high rates of morbidity and mortality in both communities and hospitals, the frequency of bacterial infection is quite high.2 However, the development of various antibacterial agents which act through different mechanisms have drastically changed the modern medicine. The "golden age" of antibiotic discovery, roughly from the 1940s to the 1970s, produced nearly all of the compounds that are still used today. Since the 1980s, new antibiotics have primarily been created by changing the side chains of already-known compounds.1 Cephalosporins are broad-spectrum antibiotics used to manage a wide-variety of infections of gram-positive and gram-negative bacteria.3 The five generations of Cephalosporins are frequently prescribed and administered many times as first-line therapy for infections ranging from mild to severe ones, from an uncomplicated cellulitis or urinary tract infection, to pyelonephritis, bacteraemia or septic shock. Cephalosporin has become an important part of hospital formularies.4 This antibacterial agent was isolated from the fungus Cephalosporium acremonium by Brotzu in 1948. Cephalosporins are the β- lactam antibiotics similar in action to penicillins, which are known to affect the transpeptidation reaction during peptidoglycan synthesis and thereby inhibit the cell wall synthesis.5 With isolation of the active nucleus of cephalosporin C, 7-aminocephalosporanic acid, and with the addition of side chains, it became possible to produce semisynthetic compounds with antibacterial activity very much greater than that of the parent substance resulting in the development of five-generations of Cephalosporins.
Chemistry: Regardless of the nature of their side chains or their affinity for the enzyme, compounds containing 7-aminocephalosporanic acid are relatively stable in diluted acid and relatively resistant to penicillinase. Changes in antibacterial activity are linked to changes at position 7 of the β-lactam ring. The drugs' metabolism and pharmacokinetic properties are altered by substitutions at position 3 of the dihydrothiazine ring.6 Mechanism of action: Cephalosporins are antibiotics with bactericidal activity. The bacterial cell wall consists of glycopeptide polymers, an N-Acetyl muramic acid and N-Acetyl Glucosamine (NAM-NAG) amino-hexose backbone linked via bridges between amino acid side chains. In gram-positive microorganisms, the cell wall is 50–100 layers thick whereas, in gram-negative bacteria, it is only 1 or 2 layers thick. The cross-linking is catalysed by a transpeptidase, the enzyme that cephalosporins inhibit, thereby causing cell lysis (cell bust) and death. In gram-negative bacteria, cephalosporins enter the cell through the porins in order to exhibit the above mechanism.7
Different classes of cephalosporins:
A different type of generations of the Cephalosporins were based on the time of discovery and this trend was followed until the third-generation cephalosporins. However, the drugs in the fourth and fifth generations were classified according to their identified activity against selected organisms. The antimicrobial spectrum shifts from grampositive bacteria to gram-negative bacteria with increasing generations of Cephalosporins. The antimicrobial spectrum of Cephalosporins has been described in Table 01. However, none of the cephalosporins are known to be active against atypical respiratory pathogens. The common side effects (ADR) associated with Cephalosporins are hypersensitivity reactions and diarrhea. Some cephalosporins are found to be potentially nephrotoxic in nature which require dose modifications. The overviews of various drugs, doses along with their common drugs have been described in Table 02.
Figure 1: Flowchart illustrating the mechanism of action of Cephalosporins
First-generation Cephalosporins
The first-generation cephalosporins, also called as ‘Narrow-spectrum cephalosporins’ (Oral-Cephradine, Cephalexin, Cefadroxil and parenterals like Cefazolin, Cephalothin, Cephapirin), are known to have good activity against gram-positive cocci like Staphylococcus Aureus, Staphylococcus Epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, Anaerobic streptococcus and modest activity against gram-negative rods like Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis. The most commonly used agents are Cephalexin and Cefazolin. Cephalexin is the prototype drug of the first generation, oral cephalosporins. Cefazolin has the longest duration of action in comparison to the other first-generation parenterals with well penetration into the bones. However, these drugs have poor Cerebrospinal fluid (CSF) penetration.
Second-generation Cephalosporins
The second-generation cephalosporins, also called as ‘Intermediate-spectrum cephalosporins’ (Oral- Cefaclor, Cefprozil, Cefuroxime axetil and Parenterals like Cefuroxime sodium, Cefoxitin, Cefotetan), have enhanced activity against gram- negative micro-organisms which include gram-negative cocci like Neisseria gonorrhoea, gram-negative rods like Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Hemophilus influenzae and modest activity against gram-positive cocci like Staphylococcus Aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Anaerobic streptococcus. Cefuroxime and Cefoxitin are the drugs commonly used in this class. Cefuroxime sodium is the prototype drug of the second-generation parenterals having long half-life and the drug crosses the blood-brain barrier. Cefuroxime is the only second-generation drug available as oral preparation as Cefuroxime axetil and parenteral preparation are Cefuroxime sodium.
| Sr. No. | GENERATIONS | DRUGS | ANTIMICROBIAL SPECTRUM |
| 1. | First- Generation Cephalosporins (Narrow-spectrum)
| Cephradine Cephalexin Cefadroxil Cefazolin Cephalothin Cephapirin
| Gram-positive cocci Staphylococcus Aureus Staphylococcus Epidermidis Streptococcus pneumoniae Streptococcus pyogenes Anaerobic streptococcus Gram-negative rods Escherichia-coli (E-coli) Klebsiella pneumoniae Proteus mirabilis |
| 2. | Second-Generation cephalosporins (Intermediatespectrum)
| Cefaclor Cefprozil Cefuroxime axetil Cefuroxime sodium Cefoxitin Cefotetan
| Gram-positive cocci Staph. Aureus Streptococcus pneumoniae Streptococcus pyogenes Anaerobic streptococcus Gram-negative cocci Neisseria gonorrhoea Gram-negative rods Enterobacter aerogenes Escherichia coli Klebsiella pneumoniae Proteus mirabilis Hemophilus influenza |
| 3. | Third-generation cephalosporins (Broad-spectrum)
| Cefixime Cefpodoxime axetil Ceftibutan Ceftriaxone Cefotaxime Ceftizoxime Ceftazidime Cefoperazone | Gram-positive cocci Streptococcus pneumoniae Streptococcus pyogenes Anaerobic streptococci Gram-negative cocci Neisseria gonorrhoeae Gram-negative rods Enterobacter aerogenes Escherichia coli Haemophilus influenzae Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens |
| 4. | Fourth-generation cephalosporins (Broad-spectrum) | Cefepime Cefpirome Ceftolozane
| Antibacterial coverage comparable to that of the third-generation class; however, demonstrate greater stability against Pseudomonas |
| 5. | Fifth-generation cephalosporins (Anti-MRSA drugs) | Ceftaroline Ceftobiprole
| Methicillin-resistant Staphylococcus Aureus Methicillin-susceptible Staphylococcus Aureus Methicillin-resistant Staphylococcus Epidermidis Streptococcus pneumonia Some Gram-negative bacteria No Pseudomonas coverage |
Table 1: The antimicrobial spectrum of various Cephalosporins
Third-generation Cephalosporins
The third-generation cephalosporins being the most widely used agents, also called as ‘Broad-spectrum cephalosporins’ (Oral-Cefixime, Cefpodoxime axetil, Ceftibuten and Parenterals-Ceftriaxone, Cefotaxime, Ceftizoxime, Ceftazidime, Cefoperazone), are less active against gram-positive cocci, although Ceftriaxone is known to have excellent activity. These drugs are known to be highly active against gram-negative cocci like Neisseria gonorrhoea, gram-negative rods like Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Hemophilus influenzae, Serratia marcescens. Ceftazidime is the only third-generation drug active against Pseudomonas aeruginosa, hence can be classified as 4th generation cephalosporins when classified according to the antimicrobial spectrum. Ceftriaxone has the longest half-life among all the cephalosporins, hence permitting once-a-day dosing. The drug is excreted through bile, and thus can be used in renal sufficiency. The third-generation drugs have good CSF penetration and hence can be used for the treatment of meningitis. Cefoperazone can prolong the prothrombin time, an effect that may be associated with clinically significant bleeding amongst patients receiving anticoagulation or with vitamin K deficiency; hence the drug should be used with caution.
Fourth-generation Cephalosporins
Commonly called as ‘Antipseudomonal Cephalosporins’, these agents (Parenterals- Cefepime, Cefpirome, Ceftolozane) expand their gram-negative activity to Pseudomonas aeruginosa and have weaker activity against gram-positive bacteria. However, Cefepime is known to have a similar spectrum as that of ceftriaxone.
Fifth-generation Cephalosporins:
Anti-MRSA Cephalosporins are the agents with structural modifications which allows binding to and inactivation of the altered PBPs expressed by Methicillin-resistant Staphylococcus Aureus (MRSA), Methicillin-resistant Staphylococcus Epidermidis (MRSE), and Penicillin-resistant Streptococcus pneumoniae. The gram-negative spectrum of this class is similar to that of the third-generation agents. However, Ceftobiprole is found to be active against Pseudomonas also.
Combining Cephalosporins with β- lactamase inhibitors
β- lactamases are a family of enzymes produced by many gram-positive and gram-negative bacteria that inactivates β- lactam antibiotic by opening the β- lactam ring, which in turn causes bacterial resistance. Hence β-lactamase inhibitors are combined with Cephalosporins for enhanced activity of Cephalosporin. The Cephalosporins commonly used in combination with β- lactamase inhibitors are:
Ceftazidime+Avibactam,
Cefoperazone+Sulbactam,
Ceftolozane+Tazobactam.
Mechanisms Of Bacterial Resisatnce to Cephalosporins
The global public health threat posed by the emergence of harmful microorganisms resistant to antibiotics is significant. Antibiotic resistance genes, however, are not just found in medical settings; they are also broadly distributed in a variety of bacterial communities in the environment. High morbidity and mortality rates were seen in the pre-antibiotic era as a result of simple infections. Antimicrobials were later developed, owing to the brilliant minds of Sir Alexander Fleming and Paul Ehrlich, and they let humanity survive the death blow from microbial illnesses.8, 9 Antibiotic-producing bacteria contain a wide range of complex defense mechanisms to protect themselves from their own antibiotics. It is only natural that organisms which produce antibiotic would also have defenses against those very same drugs. Furthermore, it is also thought that the coexistence of producer and non-producer environmental bacteria led to the co evolution of resistance mechanisms in that bacterium.8 A summary of different mechanisms of resistance has been represented in Fig-02.
β-lactamases
β-lactamases breaks the β-lactam ring rendering the cephalosporin inactive. β-lactamases act at the base of the β-lactam ring, severing the bond between carbon ‘C’ and nitrogen ‘N’ (opening the ring). The fundamental structure of cephalosporins turns inactive. Cephalosporins are rendered inactive because of this structural alteration preventing cephalosporin interaction with transpeptidase. Cephalosporins are more stable to many β-lactamases that would degrade the penicillins. However, there may be strains of Klebsiella and E. coli that will still be able to bind as well as hydrolyze cephalosporins.
Alteration of the porin channels
Porins are proteins found in the outer membrane that influence cellular permeability and antibiotic resistance. In other words, it serves as a point of entry for cephalosporins to the cell wall. An outer membrane encloses the peptidoglycan cell wall in gram-negative bacteria. Cephalosporins must cross these porins in the outer membrane of a gram-negative bacterium in order to enter the cell. By altering the porin channels, some bacteria are able to develop a resistance to cephalosporins, preventing them from inhibiting cell wall synthesis.
Alteration of molecular structure of transpeptidase
By alteration of cephalosporin binding to transpeptidase, some bacteria can produce resistance to cephalosporins. Usually, a point mutation in the cephalosporin binding pocket causes this. A point mutation is a type of genetic modification in which only one nucleotide base from the DNA or RNA sequence of an organism is altered, added, or removed. Hence, a cephalosporin cannot inhibit the cell wall synthesis if it cannot bind to transpeptidase.
Up regulation of cephalosporin efflux pumps
Efflux of antibiotics is another commonly used mechanism for self-resistance, although it usually occurs in conjunction with other mechanisms, such as modification of the antibiotic or the target.8 Some bacteria can boost the efflux pumps that actively move a cephalosporin out of the cell once it has entered by increasing efflux. Cephalosporin efflux, on the other hand, lowers the intracellular concentration of cephalosporins and lessens their ability to block cell wall formation, which promotes bacterial survival.
Figure 2: Summary of different mechanisms of resistance by Cephalosporins
Antibiotic-producing bacteria contain a wide range of complex defense mechanisms to protect themselves from their own antibiotics and it results in the development of antibiotic resistance. The various mechanisms by which bacteria develop resistance are: production of β-lactamases, alteration of the porin channels, alteration of molecular structure of transpeptidase, and upregulation of cephalosporin efflux pumps
Recent Advancements on Cephalosporins
Cefiderocol
Cefiderocol, formerly known as S-649266, is a catechol type siderophore injectable siderophore cephalosporin that is a first in its class. The spectrum of activity includes both lactose-fermenting and non-fermenting Gramnegative pathogens, including carbapenem-resistant Enterobacterales. This structure and its distinct mechanism of action confer enhanced stability against hydrolysis by many β-lactamases, including extended spectrum β-lactamases and carbapenemases. The US Food and Drug Administration recently approved Cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, and it is currently being tested in phase III trials for nosocomial pneumonia and infections brought on by Gram-negative pathogens that are carbapenemresistant. For the treatment of carbapenem-resistant Gram-negative bacterial infections, patients with sepsis, urinary tract infections, and pneumonia, the mortality rate with Cefiderocol was higher than the best available therapy (Colistin).10
IV: Intravenous; IM: Intramuscular; Q4-6H- Every 4hrs to 6hrs; Q6-12H-Every 6hrs to 8hrs; Q6H-Every 6hrs; Q8H- Every 8hrs; Q12H-Every 12hrs;
Ceftobiprole
In Europe, Ceftobiprole medocaril is now accepted as an extended-spectrum cephalosporin for treating adult skin and soft tissue infections (SSTIs), such as diabetic foot infections, as well as community-acquired and nosocomial, non-ventilator-associated pneumonia, community-acquired pneumonia and hospital-acquired pneumonia (CAP and HAP). For the treatment of Methicillin-susceptible Staphylococcus Aureus (MSSA) and Methicillin-resistant Staphylococcus Aureus (MRSA), ceftobiprole was compared to various comparators (such as Vancomycin, Linezolid, and Ceftazidime) with the following data: - Methicillin-resistant S. aureus (MRSA; 55.6 vs. 22.2%) and methicillin-sensitive Staphylococcus aureus (MSSA; 44.4 vs. 46.7%). In the ceftobiprole group, the 30-day all-cause death rate was 8.9% (4/45) compared to 16.0% (8/50) in the comparison group. In penicillin-allergic patients with severe gram-positive infections, ceftobiprole is also crucial. A daptomycin-based strategy combined with a ceftobiprole adjunct also appears promising in terms of clinical applicability for the treatment of endocarditis.11
| DRUGS | DOSAGE | INDICATION | DOSE ADJUSTMENT | ||
| RENAL IMPAIRMENT | HEPATIC IMPAIRMENT | ||||
First- Generation Cephalosporins (Narrow-Spectrum Cephalosporin) | |||||
| ORAL | Cephradine | 250-500mg Q6- 12H |
| Yes | No |
| Cephalexin | 250-500mg Q6H | Yes | No | ||
| Cefadroxil | 500mg Q12H | Yes | No | ||
PARENTERAL (IV/IM) | Cefazolin | 1-2gm Q6H | Yes | No | |
| Cephalothin | 1-2gm Q4-6H | Yes | No | ||
| Cephapirin | 500mg-1gm Q4-6H | Yes | No | ||
Second-Generation Cephalosporins (Intermediate-spectrum Cephalosporins) | |||||
| ORAL | Cefaclor | 250-500mg Q8H |
| Yes | No |
| Cefprozil | 250-500mg Q12-24H | Yes | No | ||
| Cefuroxime | 250-500mg Q8-12H | Yes | No | ||
PARENTERAL (IV/IM) | Cefuroxime Sodium | 750mg-1.5gm Q8-12H | Yes | No | |
| Cefoxitin | 1-2gm Q4-6H | Yes | No | ||
| Cefotetan | 1-2gm Q12H | Yes | No | ||
Third-Generation Cephalosporins (Broad-spectrum Cephalosporin’s) | |||||
| ORAL | Cefixime | 200-400mg Q12-24H |
| Yes | No |
| Cefpodoximeaxetil | 200mg Q12H | Yes | No | ||
| Ceftibuten | 400mg Q12H | Yes | No | ||
PARENTERAL (IV/IM) | Ceftriaxime | 1-2gm Q12H | No | No | |
| Ceftotaxime | 1-2gm Q8H | Yes | No | ||
| Ceftizoxime | 1-2gm Q8-12H | Yes | No | ||
| Ceftazidime | 1-2gm Q8H | Yes | No | ||
| Cefoperazone | 1-2gm Q12H | Yes | Close monitoring | ||
Fourth-Generation Cephalosporins (Broad-spectrum Cephalosporin’s) | |||||
PARENTERAL (IV/IM) | Cefepime | 500mg-2gm Q12H |
| Yes | NO |
| Cefpirome | 1-2gm Q12H | Yes | NO | ||
| Ceftolozane | 1-2gm Q8H | Yes | NO | ||
Fifth-Generation Cephalosporins (Broad-spectrum Cephalosporin’s) | |||||
PARENTERAL (IV/IM) | Ceftaroline | 600mg Q12H |
| Yes | No |
| Ceftobiprole | 500mg Q12H | Yes | No | ||
Table 2: List of Cephalosporins based on their generations
Ceftobiprole
In Europe, Ceftobiprole medocaril is now accepted as an extended-spectrum cephalosporin for treating adult skin and soft tissue infections (SSTIs), such as diabetic foot infections, as well as community-acquired and nosocomial, non-ventilator-associated pneumonia, community-acquired pneumonia and hospital-acquired pneumonia (CAP and HAP). For the treatment of Methicillin susceptible Staphylococcus Aureus (MSSA) and Methicillin-resistant Staphylococcus Aureus (MRSA), ceftobiprole was compared to various comparators (such as Vancomycin, Linezolid, and Ceftazidime) with the following data: - Methicillin-resistant S. aureus (MRSA; 55.6 vs. 22.2%) and methicillin-sensitive Staphylococcus aureus (MSSA; 44.4 vs. 46.7%). In the ceftobiprole group, the 30-day all-cause death rate was 8.9% (4/45) compared to 16.0% (8/50) in the comparison group. In penicillin allergic patients with severe gram-positive infections, ceftobiprole is also crucial. A daptomycin-based strategy combined with a ceftobiprole adjunct also appears promising in terms of clinical applicability for the treatment of endocarditis.11
Ceftaroline
The drug Ceftaroline has a broad range of activity against Gram-positive bacteria that commonly cause CAP and SSTIs, such as MSSA and MRSA, as well as against some resistant Staphylococcus aureus strains (Vancomycin intermediate, heterogeneous vancomycin intermediate, vancomycin-resistant, or daptomycin non-susceptible) and Multidrug-resistant (MDR) Streptococcus pneumoniae.12 Ceftaroline had a 64.9% combined clinical cure rate compared to a 69.7% monotherapy cure rate. Ceftaroline treatments were incredibly successful as first-line treatments in patients with right-sided endocarditis (80.8%) and MRSA (77.3%), as well as in general (75.0%).13
Although there is little information on the medication concentrations in CSF, ceftaroline may also be used to treat severe infections, such as primary (such as post-traumatic) and secondary (such as post-surgical) bacterial meningitis.14 Vancomycin and ceftaroline both have comparable antibacterial efficacy in treating MRSA in an experimental meningitis model. In their most recent comprehensive study, Pani et al. verified the use of ceftaroline as the fifth off-label indication for meningitis.15, 16
Ceftazidime/Avibactam
A third-generation cephalosporin and the non-lactam/lactamase inhibitor avibactam are combined intravenously, which has activity against P. aeruginosa, Extended spectrum Beta-lactamases (ESBL)-producing bacteria, and bacteria that produce carbapenemases. Ceftazidime/ Avibactam (C/A) has been licensed for use in the treatment of Complicated intra-abdominal infections(cIAI), Complicated urinary tract infections(cUTI), and Non-Pseudomonal (NP)-resistant infections caused by microorganisms.17,18 There was no discernible difference in the death rates between C/A alone and combination therapy. C/A was mostly administered as monotherapy (81%) for a mean length of 13 days. The 14-day mortality rate was 14 Tumbarello et al. conducted a retrospective longitudinal investigation of 138 patients with Klebsiella pneumoniae carbapenemases-producing Klebsiella Pneumoniae (KPC-Kp) bacteremia, in which C/A use was significantly associated with reduced mortality (36.5 vs. 55.8%, P = 0.05) and the only predictor that was significantly correlated with survival.20 Based on study conducted by shield et el. found that C/A had greater rates of clinical success (P = 0.006), survival (P = 0.01), and renal safety (P = 0.002) compared to regimens comprising amino glycosides and colistin.21
Cephalosporins are diverse, extremely useful group of beta-lactam antibiotics with bactericidal activity. They play a major role in treatment of various infections, ranging from mild to severe ones. The antibiotic spectra of cephalosporins, which are divided into first through fifth generations, can be grouped roughly by generation, with increasing gram-negative activity in each higher generation and decreasing gram-positive activity with increasing generation. The knowledge of the basic chemistry helps in understanding the pharmacokinetic, antimicrobial and toxicological profiles of the cephalosporins, thereby ensuring rational selection of antibiotics for various infections. The emergence of cephalosporin resistant strains of various infectious species should be considered while making treatment decisions. The new cephalosporins are the foundation for the real warning signs to open up new and interesting possibilities for serious infections in the future. In future, patients will be addressed with the desirable approach to various infections in terms of their clinical situation, inherent features of the host, the sensitivity profile, and local epidemiology, for which evidence of the use of new cephalosporin in the treatment of severe infections will fill the remaining gaps.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
